SOV Therapeutics Inc.

Wednesday, February 20, 2013

• SOV Therapeutics Receives US Orphan Drug Designation for the Use of Oral Testosterone Undecanoate in the Treatment of Constitutional Delay in Growth and Puberty in Adolescent Boys (14-17 Years of Age)

  SOV Therapeutics Inc. today announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for the use of oral testosterone undecanoate, a pro-drug of testosterone, ... read more